Company NewsRAG-01 Ractigen Therapeutics Secures FDA Fast Track Designation for RAG-01, a First-in-Class saRNA Therapy SUZHOU, China, May 21, 2024 – Ractigen Therapeutics, a pioneering developer of small activating RNA…ractigenMay 21, 2024
Company NewsRAG-01 Ractigen Therapeutics Announces FDA Approval for RAG-01, a First-in-Class saRNA Therapy for BCG-Unresponsive NMIBC JIANGSU, China, April 26, 2024 — Ractigen Therapeutics, a leader in the development of small…ractigenApril 26, 2024
Company NewsRAG-01 Ractigen Announces First Patient Dosed in the Phase I Clinical Trial of RAG-01 for NMIBC JIANGSU, China, April 3, 2024 – Ractigen Therapeutics, a pioneer in small activating RNA (saRNA) therapeutics,…ractigenApril 3, 2024
Company NewsRAG-01 Ractigen Therapeutics Advances into Clinical Stage with Groundbreaking saRNA Drug, RAG-01 JIANGSU, China, Dec. 06, 2023 — Ractigen Therapeutics, a leader in the field of small…ractigenDecember 6, 2023